Abstracts tagged "juvenile scleroderma and morphea"

Abstract Number: 101 • 2017 Pediatric Rheumatology Symposium
Defining Active Features of Juvenile Localized Scleroderma
Suzanne Li¹, Xiaohu Li², Elena Pope³, Katie G. Stewart⁴, Gloria Higgins⁵, C. Egla Rabinovich⁶, Kathleen O'Neil⁷, Kathleen Haines⁸, Ronald Laxer⁹, Marilynn Punaro¹⁰, Heidi Jacobe¹¹, Knut Wittkowski¹², Themba Nyirenda¹³, Ivan Foeldvari¹⁴ and Kathryn S. Torok¹⁵, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ²Mathematical Sciences, Stevens Institute of Technology, Hoboken, NJ, ³Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatrics, Nationwide Children's Hospital, Columbus, OH, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatrics, Indiana University, Indianapolis, IN, ⁸Joseph M Sanzari Children’s Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁹Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Texas Scottish Rite Hospital for Children, Dallas, TX, ¹¹Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Rockefeller University, New York, NY, ¹³Hackensack University Medical Center, Hackensack, NJ, ¹⁴Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹⁵Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Juvenile localized scleroderma (jLS) is the most common form of childhood scleroderma. Because of its chronicity and association with extracutaneous involvement, children are at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].